Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cambrius is a synthetic biology company that leverages computational protein design and mycelium-based technology to develop high-performance, sustainable materials. Based in Chile and accelerated through IndieBio, the company focuses on creating bio-fabricated alternatives to traditional animal and synthetic leathers for the fashion and automotive industries. Their platform enables the engineering of specific functional properties into biological materials, aiming to replace carbon-intensive manufacturing processes with scalable biomanufacturing solutions. By combining advanced protein engineering with fungal biotechnology, Cambrius seeks to deliver materials that match or exceed the durability and aesthetics of conventional textiles while significantly reducing environmental impact.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cambrius.